Ozempic\u00ae was first added to the FDA Drug Shortage Database in August 2022 and stayed there in some form for over two years. The shortage was finally declared resolved in early 2025, alongside Wegovy\u00ae, after Novo Nordisk’s manufacturing expansion caught up. In 2026, the official answer is that there is no Ozempic shortage. The practical answer is more complicated.<\/p>\n
This piece covers where Ozempic supply actually stands, why diabetes patients still see periodic stock gaps, and what alternatives prescribers consider when Ozempic isn’t where you need it.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
No, not on the FDA Drug Shortage Database as of 2026.<\/strong> Novo Nordisk and the FDA jointly declared the semaglutide injection shortage resolved on February 21, 2025. That includes both the Wegovy obesity formulation and the Ozempic diabetes formulation, which use the same molecule at different approved strengths.<\/p>\n Quick Answer: Ozempic was removed from the FDA shortage list in February 2025 alongside Wegovy<\/p>\n Pharmacy-level gaps persist. The 0.5 mg and 1 mg pens, which are the standard diabetes maintenance doses, are dispensed in the highest volume and run short most often. A NACDS pharmacy survey in early 2026 reported that 24% of pharmacies had at least one Ozempic strength out of stock during a typical week.<\/p>\n The 0.25 mg starter and 0.5 mg titration doses are the most consistently available. The 2 mg high-dose pen, approved in 2022 for diabetes patients who need additional A1C reduction, sees the longest delays because it’s the lowest-volume strength and shares fill-finish capacity with Wegovy 1.7 mg.<\/p>\n Two structural reasons.<\/strong> First, semaglutide drug substance is hard to make. It’s a 31-amino-acid synthetic peptide that requires sequential coupling reactions and complex purification. Novo Nordisk runs the largest peptide synthesis capacity in the world and still allocates production between Ozempic, Wegovy, and Rybelsus\u00ae.<\/p>\n Second, U.S. diabetes prescribing of GLP-1 agonists keeps growing. The ADA 2025 Standards of Care recommend GLP-1 agonists as preferred agents for patients with established cardiovascular disease or chronic kidney disease, alongside or before metformin in some cases. SELECT (Lincoff et al. 2023 NEJM) and FLOW (Perkovic et al. 2024 NEJM) both expanded the indication picture.<\/p>\n Demand isn’t slowing. Novo’s investor guidance for 2026 forecasts low-double-digit U.S. dispensing growth for semaglutide injection.<\/p>\n Same molecule, different brand and different approved doses.<\/strong> Ozempic is FDA-approved for type 2 diabetes at 0.25 mg, 0.5 mg, 1 mg, and 2 mg weekly. Wegovy is FDA-approved for chronic weight management at 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg weekly. The pen designs differ. The active ingredient is the same semaglutide.<\/p>\n Insurance coverage rules differ sharply. Most plans cover Ozempic only for type 2 diabetes with documented A1C and prior metformin or other agents. Most plans cover Wegovy only for obesity with BMI thresholds and lifestyle program participation. Prescribing one for the other indication is off-label and generally not covered.<\/p>\n If you’re a diabetes patient who also wants weight loss, Ozempic is the on-label path. If you’re a weight-management patient with cardiovascular disease, Wegovy plus the SELECT indication is the on-label path.<\/p>\n Yes, prescribers do prescribe Ozempic off-label for obesity, but the practice is less common in 2026 than it was during the 2022 to 2024 shortage when Wegovy was effectively unobtainable.<\/strong> Now that Wegovy supply has improved, both prescribers and pharmacists generally route weight-management patients to the labeled drug.<\/p>\n Off-label Ozempic for weight loss usually means full cash pay. Novo Nordisk’s savings card and the NovoCare patient assistance program don’t apply to off-label use. Pharmacy retail price for Ozempic is roughly $950 to $1,050 per month in 2026, depending on strength.<\/p>\n The clinical evidence for semaglutide in obesity comes from STEP 1 (Wilding et al. 2021 NEJM), which used 2.4 mg, a dose only available in Wegovy. The closest Ozempic strength, 2 mg, has weaker obesity-specific evidence.<\/p>\n For type 2 diabetes, several options work.<\/strong> Mounjaro\u00ae (tirzepatide) is the most direct alternative, with SURPASS trials showing larger A1C reductions than semaglutide in head-to-head comparisons. SURPASS-2 (Frias et al. 2021 NEJM) reported A1C reduction of 2.30 percentage points with 15 mg tirzepatide versus 1.86 with 1 mg semaglutide.<\/p>\n Trulicity\u00ae (dulaglutide) is another weekly GLP-1 agonist with a long track record (REWIND, Gerstein et al. 2019 Lancet). Its dose strengths run 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg weekly. Cardiovascular outcomes are favorable.<\/p>\n Rybelsus is the oral version of semaglutide, taken daily on an empty stomach. PIONEER trials demonstrated A1C and weight benefits, though absolute reductions are smaller than injectable forms.<\/p>\n For patients who need additional non-GLP-1 options, SGLT2 inhibitors like Jardiance (empagliflozin) and Farxiga (dapagliflozin) have cardiovascular and renal benefits independent of GLP-1 agonism.<\/p>\n Key Takeaway: Off-label prescribing of Ozempic for obesity has dropped sharply since Wegovy supply recovered<\/p>\n Possibly, with prescriber input.<\/strong> Tirzepatide’s dual GIP and GLP-1 mechanism produces larger A1C reductions and weight loss than semaglutide in head-to-head trials. SURPASS-2 showed that. Side effect profiles are similar though tirzepatide tends to cause more constipation and semaglutide more diarrhea, anecdotally.<\/p>\n Switching requires a new prior authorization in most insurance plans because they’re separate drug classes from a payer’s perspective even though clinically they overlap. Restart titration at the lowest dose, 2.5 mg weekly, for four weeks. Don’t assume your Ozempic dose translates.<\/p>\n The cost picture matters too. Mounjaro list price is higher than Ozempic in 2026. Some plans cover Mounjaro with smaller copays because Lilly has aggressive PBM contracts. Others charge more. Check your specific plan.<\/p>\n The FDA’s 503B compounding exception for semaglutide ended in May 2025.<\/strong> State-licensed 503A pharmacies can still compound semaglutide on a patient-specific basis when there’s a documented clinical reason commercial product doesn’t work. For a diabetes patient who needs a non-standard dose, has allergies to inactive ingredients, or needs a combination, compounding is still possible.<\/p>\n Most diabetes patients who simply can’t fill Ozempic should switch brands rather than pursue compounding. The clinical bar for personalized compounding requires more than commercial supply gaps. Compounding is also generally not covered by insurance for diabetes use.<\/p>\n TrimRx works with licensed compounding pharmacies. If you’re a weight-management patient who finds compounded semaglutide a better fit clinically and financially, the free assessment quiz reviews your situation.<\/p>\n List prices in 2026 are stable.<\/strong> The Inflation Reduction Act’s Medicare price negotiation included semaglutide in the second round of negotiated drugs, with new Medicare prices effective January 2027. Private insurance pricing is renegotiated annually with PBMs, and 2026 contracts mostly held flat versus 2025.<\/p>\n Cash retail prices vary widely by pharmacy. GoodRx coupons can shave $100 to $200 per month off retail, depending on location and strength. Costco often beats other chains on cash pricing.<\/p>\n The Novo Nordisk Patient Assistance Program covers Ozempic at zero cost for patients meeting income thresholds (generally 400% of federal poverty level). The savings card brings copays down to $25 per month for many insured patients.<\/p>\n Three things. First, get prescriptions written for 90-day supply if your insurance allows it, and use a mail-order pharmacy. That eliminates the monthly scramble. Second, stay 2 weeks ahead on refills. Order when you have 14 days left, not 3. Third, ask your prescriber to write multiple authorized refills upfront, so a single insurance approval doesn’t have to be re-done each month.<\/p>\n If you live in an area with periodic supply gaps, talk to your prescriber about a contingency: a Mounjaro or Trulicity prescription you can fill if Ozempic goes out for more than a week. Having that pre-approved removes the panic factor.<\/p>\n Bottom line: Alternatives for diabetes include Mounjaro, Trulicity, oral Rybelsus, and SGLT2 inhibitors<\/p>\n Per FDA, yes, since February 2025. Pharmacy-level supply gaps still happen but no systemic shortage exists.<\/p>\n Some prescribers permit it with careful counting, but the pens are not designed for variable dosing the way insulin pens are. Splitting risks dose inaccuracy. Don’t do this without your prescriber’s guidance.<\/p>\n Pharmacy-level supply lags FDA listings. Individual pharmacies, wholesalers, and regional distribution centers run out before a national shortage triggers. Call a different pharmacy.<\/p>\n The clinical trial evidence favors Wegovy 2.4 mg for obesity. STEP 1 averaged 14.9% weight loss at 68 weeks. Trials of Ozempic 2 mg in obese non-diabetic patients are limited.<\/p>\n Yes, for type 2 diabetes with milder targets. Oral semaglutide produces smaller A1C and weight reductions than injectable forms but avoids the injection and shares the molecule. PIONEER trial data supports its use.<\/p>\n TrimRx prescribes compounded semaglutide and tirzepatide through partnered licensed pharmacies, not the brand-name Ozempic pen. For brand Ozempic, you’ll need a traditional prescription path.<\/p>\n Talk to your prescriber. Most experts recommend resuming at your last dose if the gap is under two weeks and downtitrating one step if the gap is longer. Don’t self-bridge.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" Ozempic was first added to the FDA Drug Shortage Database in August 2022 and stayed there in some form for over two years.<\/p>\n","protected":false},"author":11,"featured_media":93226,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Ozempic Shortage: Status and Alternatives in 2026","_yoast_wpseo_metadesc":"Ozempic was first added to the FDA Drug Shortage Database in August 2022 and stayed there in some form for over two years.","_yoast_wpseo_focuskw":"ozempic shortage status","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[8],"tags":[39,47],"class_list":["post-90397","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-ozempic","tag-ozempic","tag-shortage"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90397","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90397"}],"version-history":[{"count":1,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90397\/revisions"}],"predecessor-version":[{"id":91750,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90397\/revisions\/91750"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/93226"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90397"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90397"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90397"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Why Is Ozempic Still Hard to Find Sometimes?<\/h2>\n
What’s the Difference Between Ozempic and Wegovy?<\/h2>\n
Can You Take Ozempic for Weight Loss?<\/h2>\n
What Alternatives Exist If Ozempic Isn’t Available?<\/h2>\n
Should I Switch From Ozempic to Mounjaro?<\/h2>\n
What About Compounded Semaglutide for Diabetes Patients?<\/h2>\n
Are Ozempic Prices Going Up?<\/h2>\n
How Can I Avoid Getting Stuck Without Ozempic?<\/h2>\n
FAQ<\/h2>\n
Is the Ozempic Shortage Definitely Over?<\/h3>\n
Can I Split Ozempic Doses to Make a Pen Last Longer?<\/h3>\n
Why Does My Pharmacy Say Ozempic Is on Backorder If It’s Not on the FDA Shortage List?<\/h3>\n
Does Ozempic 2 Mg Work as Well as Wegovy 2.4 Mg for Weight Loss?<\/h3>\n
Is Rybelsus a Real Alternative to Ozempic?<\/h3>\n
Does TrimRx Prescribe Ozempic?<\/h3>\n
What’s the Safest Way to Bridge a Gap If I Run Out for a Week?<\/h3>\n